Company Prepares to Commercialize New Endometrial Indication as Adoption for its Breast Cancer Application Continues to Grow.

SUNNYVALE, Calif. August 11, 2008 – Xoft, Inc., developer of Electronic Brachytherapy (eBx), a proprietary cancer treatment platform, announced today that the company has closed its Series E preferred stock financing, raising a total of $25 million in additional funding. An award-winning new method of delivering non-isotope-based radiation, the Axxent® Electronic Brachytherapy System uses a miniaturized X-ray source that can deliver localized and targeted radiation treatment in virtually any clinical setting under the supervision of a radiation oncologist. All of Xoft's major investors participated in the Series E financing, which was led by Chicago Growth Partners, a new investor in Xoft. Additionally, as part of the financing, Arda Minocherhomjee, Ph. D., managing partner of Chicago Growth Partners, joined the Xoft Board of Directors. 

ELECTRONIC BRACHYTHERAPY ACCURATELY DELIVERS NON-RADIOACTIVE THERAPY DIRECTLY TO BREAST AND ENDOCAVITARY CANCER SITES Research Studies and Initial Clinical

Experience Presented at the AAPM Validate That Electronic Brachytherapy Consistently Delivers Radiation Therapy as Planned.

HOUSTON, July 28, 2008 – Xoft, Inc. today announced that the Axxent® High Dose Rate (HDR) X-ray Source has been selected to receive an R&D 100 Award from R&D Magazine as one of the year’s most technologically significant products.  Established by the editors of R&D Magazine in 1963, the R&D 100 Awards are designed to recognize significant technological achievements and products that leapfrog current technology and that provide simple, elegant solutions to complex or long-standing technical or practical problems. 

XOFT RECOGNIZED WITH R&D 100 AWARD

R&D Magazine Selects Axxent® Miniature Brachytherapy X-ray Source as One of the 100 Most Technologically Significant Products of the Past Year.

SUNNYVALE, Calif., July 24, 2008 – Xoft, Inc. today announced that the Axxent® High Dose Rate (HDR) X-ray Source has been selected to receive an R&D 100 Award from R&D Magazine as one of the year’s most technologically significant products.  Established by the editors of R&D Magazine in 1963, the R&D 100 Awards are designed to recognize significant technological achievements and products that leapfrog current technology and that provide simple, elegant solutions to complex or long-standing technical or practical problems. 

FROST & SULLIVAN HONORS XOFT FOR ONCOLOGY INNOVATION

Xoft, Inc. today announced that Frost & Sullivan has bestowed the 2008 North American Medical Devices Healthcare Innovation Award in Oncology to Xoft.

SUNNYVALE, Calif., July 23, 2008 – Xoft, Inc. today announced that Frost & Sullivan has bestowed the 2008 North American Medical Devices Healthcare Innovation Award in Oncology to Xoft.  Recognizing excellence in the development of the Axxent® Electronic Brachytherapy System, the Frost & Sullivan Award highlights Xoft’s ability to develop advanced oncology products to fit the growing needs of the medical devices industry.

FIRST BREAST CANCER PATIENT RECEIVES TREATMENT IN NATIONAL ELECTRONIC BRACHYTHERAPY REGISTRY LAUNCHED BY THREE PHYSICIAN SOCIETIES

Multi-Disciplinary Oversight Panel Includes American Brachytherapy Society, American Society of Breast Surgeons and American College of Radiation Oncology

SUNNYVALE, Calif., June 24, 2008 – Xoft, Inc. today announced the launch and of the EXIBT Study (Electronic Xoft Intersociety Brachytherapy Trial), a national Electronic Brachytherapy patient registry under oversight from three national physician societies, the American Brachytherapy Society (ABS), the American Society of Breast Surgeons (ASBrS), and the American College of Radiation Oncology (ACRO). The first patient was successfully enrolled and treated in the registry by Drs. Peter Beitsch of the Dallas Breast Center and Dr. Timothy Nichols of the Northpoint Cancer Center in Dallas, Texas.

With an enrollment goal of 400 patients, the objective of the multi-center study is to assess the long-term safety and efficacy of the Xoft Axxent® Electronic Brachytherapy System for the treatment of early stage breast cancer patients. The primary endpoint is the measurement and quantification of skin and subcutaneous toxicities through five year follow-up. An important additional primary endpoint includes a quality of life questionnaire based on patient experience with this new form of radiation therapy. Secondary endpoints assess local-regional breast failure and patient survival through five years as well as device performance.  

FDA CLEARS NEW APPLICATORS FOR ENDOMETRIAL CANCER TREATMENT WITH XOFT’S AXXENT® ELECTRONIC BRACHYTHERAPY SYSTEM

Second Treatment Indication on Heels of Multi-Use Clearance for Axxent® System  Strengthens the Creation of a New Platform in Radiation Therapy

SUNNYVALE, Calif., May 21, 2008 – Xoft, Inc., today announced that it has received clearance from the U.S. Food & Drug Administration (FDA) for applicators to be used with the Axxent® Electronic Brachytherapy System for the treatment of endometrial cancer. Previously cleared for accelerated treatment of early stage breast cancer, the Axxent System, a proprietary technology platform designed to deliver localized, non-radioactive, isotope-free radiation treatment in minimally-shielded clinical settings, also recently received expanded FDA Clearance for use in the treatment of other cancers or conditions where radiation therapy is indicated.

RESEARCH PRESENTED AT AMERICAN BRACHYTHERAPY SOCIETY FURTHER VALIDATES USE OF ELECTRONIC BRACHYTHERAPY

Multiple Studies Support Use of Non Isotope-Based Therapy in Early Stage Breast Cancer and Explore Potential Cervical and Endometrial Applications

BOSTON, May 5, 2008 – The performance of Electronic Brachytherapy, a proprietary treatment platform designed to deliver non-radioactive therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue, is the focus of a panel discussion and five research studies accepted for presentation at the 2008 World Congress of Brachytherapy hosted by the American Brachytherapy Society (ABS). According to Xoft, Inc., developer of the Axxent® Electronic Brachytherapy System, the studies by radiation oncologists, medical physicists, and researchers from McGill University, Rhode Island Hospital, Rush University, Little Company of Mary, and Xoft bolster a growing body of research supporting use of Electronic Brachytherapy in the treatment of early stage breast cancer and exploring potential cervical and endometrial applications in which non isotope-based brachytherapy could be used to precisely deliver dose to targeted tissue.
 

XOFT MEDICAL DIRECTOR RECOGNIZED BY GOTHAM PRIZE 
FOR CANCER RESEARCH 

Mark Carol, MD, Receives Ira Sohn Conference Foundation Prize in Pediatric Oncology for Novel Approaches for Using X-ray Based Radiation Therapy to Treat Cancer Patients

SUNNYVALE, Calif., April 3, 2008 – Xoft consulting medical director, Mark Carol, MD, has received the Ira Sohn Conference Foundation Prize in Pediatric Oncology for his research focused on novel approaches for using KV X-ray-based radiation therapy to treat patients with cancer.

FDA CLEARS EXPANDED USE OF XOFT’S AXXENT® ELECTRONIC BRACHYTHERAPY SYSTEM FOR ALL RADIATION THERAPY INDICATIONS

FDA Clearance Validates Platform Designed to Deliver Electronic Xray-Based Therapy Directly to Cancer Sites in Minimally Shielded Clinical Settings

SUNNYVALE, Calif., March 17, 2008 — Xoft, Inc., today announced that it has received expanded clearance from the U.S. Food & Drug Administration (FDA) for the Axxent® Electronic Brachytherapy System, a proprietary technology platform designed to deliver localized, non-radioactive, isotope-free radiation treatment in minimally-shielded clinical settings. Previously cleared for accelerated treatment of early stage breast cancer, the Axxent System is now cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated.

XOFT TO PRESENT AT THE 26TH ANNUAL JP MORGAN HEALTHCARE CONFERENCE

CEO to Provide Update on the Clinical and Commercial Adoption of the
Axxent® Electronic Brachytherapy System  

 FREMONT, Calif., Jan. 3, 2008 — Xoft, Inc., developer of the Axxent® Electronic Brachytherapy System, a proprietary cancer treatment platform that utilizes X-rays to deliver non-radioactive, isotope-free radiation therapy directly to cancer sites, today announced that it will present at the 26th Annual JP Morgan Healthcare Conference. Xoft president and CEO Michael Klein will present on Thursday, January 10, 2008, at 7:30am at The Westin St. Francis Hotel in San Francisco.

"We are excited to have the opportunity to provide an update on the adoption of this exciting new method of delivering internal radiation therapy since we went fully commercial in Q4 of 2007," said Klein. "With breast cancer, the first FDA cleared indication for the Axxent System, we are already seeing excellent clinical results at the 10 initial clinical sites and more than a dozen commercial sites that have committed since we went commercial. Combined with strong awareness among the oncology community and the recent establishment of Medicare reimbursement for Electronic Brachytherapy in the hospital outpatient setting, we expect rapid and widespread commercial adoption, making it available to women who want to take advantage of breast conserving therapy."

AMERICAN MEDICAL ASSOCIATION APPROVES CPT CODE FOR ELECTRONIC BRACHYTHERAPY FOR TREATMENT OF EARLY BREAST CANCER

New Code Opens Door to Broader Adoption of X-ray Based Radiation Therapy

FREMONT, Ca., July 25, 2007 — The American Medical Association (AMA) Common Procedural Terminology (CPT) Editorial Panel recently approved a CPT Code for the use of electronic brachytherapy, a novel form of high dose rate radiation therapy for the treatment of early stage breast cancer. According to Xoft, Inc., developer of the Axxent® Electronic Brachytherapy System, a proprietary cancer treatment platform, this decision is an important step in accelerating the adoption of the new treatment option that is designed to deliver targeted radiation therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue.

XOFT REACHES MILESTONE AS AXXENT^® ELECTRONIC BRACHYTHERAPY SYSTEM IS USED TO TREAT EARLY STAGE BREAST CANCER PATIENTS

Panel at American Society of Breast Surgeons Annual Meeting Reviews the Role of the Surgeon in Electronic Brachytherapy of the Breast

PHOENIX, Az., May 2, 2007 — Bringing improved patient access to a new cancer treatment that is delivered more easily and conveniently, Xoft, Inc. announced that the first breast cancer patients have been treated using the Axxent® Electronic Brachytherapy System. Designed to help reduce recurrence of breast cancer, the breakthrough new therapy for early stage breast cancer uses a miniaturized X-ray source that can deliver localized and targeted radiation treatment in virtually any clinical setting under the supervision of a radiation oncologist. The announcement was made here at the 8th Annual Meeting of the American Society of Breast Surgeons (ASBS).

WellStar Kennestone Hospital First Medical Center to Treat Early Stage Breast Cancer with New Treatment Axxent® Electronic Brachytherapy System from Xoft Offers Patients with Early Stage Breast Cancer a New Option to Reduce Recurrence of Disease

MARIETTA, Ga., April 25, 2007 — WellStar Kennestone Hospital and The Breast Center in Marietta directed by Philip Z. Israel, M.D., announced today that it has completed treatment of the first breast cancer patient with a breakthrough new therapy for early stage breast cancer. Designed to help reduce recurrence of breast cancer, the Axxent® Electronic Brachytherapy System from Xoft, Inc., uses a miniaturized X-ray source that can deliver localized and targeted radiation treatment in virtually any clinical setting under the supervision of a radiation oncologist. WellStar Kennestone is the first medical center in the world to use an Axxent™ System, bringing improved patient access to the new cancer treatment that is delivered more easily and conveniently.

Xoft, Inc., Announces Additional Funding for Breakthrough Electronic Brachytherapy Technology

FREMONT, Ca., April 4, 2007 — Xoft, Inc., developer of Electronic Brachytherapy, a proprietary cancer treatment platform, announced today that the company has closed a Series D round of financing, totaling $33.2 million in additional equity funding. Designed to help reduce recurrence of breast cancer, the Axxent™ Electronic Brachytherapy System uses a miniaturized X-ray source that can deliver localized and targeted radiation treatment in virtually any clinical setting under the supervision of a radiation oncologist.

MOMENTUM FOR XOFT'S ELECTRONIC BRACHYTHERAPY GROWS

Xoft Secures Final $10 Million to Complete $30 Million Commercialization Funding

FREMONT, Ca., July 25, 2006 — Xoft, Inc., developer of the Axxent™ Electronic Brachytherapy System, announced that six studies have been accepted for presentation at the 48th American Association of Physicists in Medicine Meeting, July 30 – August 3 in Orlando. The presentations join a growing body of research demonstrating the ability of Electronic Brachytherapy to accurately and consistently deliver the therapeutic dose as predicted though treatment planning.

FDA CLEARS XOFT’S AXXENT™ ELECTRONIC BRACHYTHERAPY SYSTEM FOR TREATMENT OF BREAST CANCER

New Technology Delivers Non-Radioactive, Localized Radiation Therapy Direct to Cancer Sites in Minimally Shielded Clinical Setting

FREMONT, Ca., January 4, 2006 — Signaling another advance in the fight against breast cancer, Xoft, Inc., today announced that it has received clearance from the U.S. Food & Drug Administration (FDA) for the Axxent™ Electronic Brachytherapy System for the treatment of breast cancer. Electronic Brachytherapy is a proprietary technology platform designed to deliver localized, non-radioactive, isotope-free radiation treatment in a minimally-shielded clinical setting under the supervision of a radiation oncologist.

90 PERCENT OF RADIATION ONCOLOGY PROFESSIONALS SURVEYED BELIEVE ELECTRONIC BRACHYTHERAPY IS AN EXCITING NEW CANCER TREATMENT TOOL

Axxent™ Electronic Brachytherapy System, Pending FDA Clearance, Highlighted as a Quantum Leap in Therapy Delivery During ASTRO Plenary Session

DENVER, Co., November 4, 2005 — Tens of thousands of women suffering from breast cancer opt for mastectomies or for lumpectomies without radiation therapy, despite significant clinical evidence demonstrating equivalent survival rates for breast conserving therapy. This may change with the widespread adoption of Electronic Brachytherapy, a new technology designed to deliver localized, non-radioactive radiation treatment directly to cancer sites, according to a survey of radiation oncology professionals at the recent American Society for Therapeutic Radiology and Oncology (ASTRO) Meeting.

DENVER, Co., October 13, 2005 — Xoft, Inc., developer of the Axxent ™ Electronic Brachytherapy System, announced that it has signed a software distribution agreement with Varian Medical Systems. The announcement was made in advance of the 47th American Society for Therapeutic Radiology and Oncology (ASTRO) Meeting, October 16-19.

ELECTRONIC BRACHYTHERAPY ACCURATELY DELIVERS NON-RADIOACTIVE RADIATION THERAPY DIRECTLY TO TUMOR SITES

Four Abstracts Presented at the American Association of Physicists in Medicine Validate That Electronic Brachytherapy Consistently Delivers Radiation Therapy as Planned

SEATTLE, Wa., July 22, 2005 — The ability of Electronic Brachytherapy to accurately and consistently deliver localized, non-radioactive radiation treatment directly to cancer sites is the focus of four research papers accepted for presentation at the 47th American Association of Physicists in Medicine Meeting, July 24 - 28 in Seattle. According to Xoft, Inc., developer of the AxxentTM Electronic Brachytherapy System, the studies continue to demonstrate that the radiation dose delivered is equal to the dose predicted through treatment planning.

RESEARCH DEMONSTRATES NON-RADIOACTIVE ELECTRONIC
BRACHYTHERAPY EQUIVALENT TO TRADITIONAL BRACHYTHERAPY

Three Abstracts Presented at the American Brachytherapy Society Meeting Show Promise for Breakthrough Breast-Conserving Cancer Treatment

SAN FRANCISCO, Ca., June 2, 2005 — The performance of Electronic Brachytherapy, a new technology designed to deliver localized, non-radioactive radiation treatment directly to cancer sites, is the focus of three research papers accepted for presentation at the 26th American Brachytherapy Society Meeting, June 1-3, 2005 in San Francisco. According to Xoft, Inc., developer of the Axxent™ Electronic Brachytherapy System, the studies bolster a growing body of research demonstrating equivalency to traditional brachytherapy.

Xoft Secures $30 Million Financing Round as Electronic Brachytherapy Breast Cancer Treatment Approaches Commercialization

FREMONT, Ca., May 6, 2005 — Xoft, Inc., a company developing electronic brachytherapy for cancer treatment, has closed a commercialization round of financing, raising $30 million. Demonstrating continued support for the proprietary, technology designed to deliver non-radioactive, isotope-free radiation treatment in virtually any clinical setting, the investment will allow Xoft to complete clinical validation studies on the Axxent™ Electronic Brachytherapy system and launch it in the multi-billion dollar breast cancer therapeutics market.

ADOPTION OF BREAST CONSERVING THERAPY MAY BE ACCELERATED THROUGH THE USE OF ELECTRONIC BRACHYTHERAPY

According to Multidisciplinary Panel at American Society of Breast Surgeons Annual Meeting, Seven Studies Demonstrate That Radiotherapy is Essential Breast Cancer Treatment Component

LOS ANGELES, Ca., April 5, 2005 — Tens of thousands of women suffering from breast cancer opt for full mastectomies or for lumpectomies without radiation therapy, despite significant clinical evidence demonstrating that lumpectomies followed by radiation therapy have equivalent survival rates to full mastectomies. Now, a new technology designed to deliver localized, non-radioactive radiation treatment directly to cancer sites may significantly increase access to radiation treatment and thus demand for breast-conserving therapy, according to a multi-disciplinary panel of physicians here at the recently concluded 6th Annual Meeting of the American Society of Breast Surgeons (ASBS).

PROPRIETARY PLATFORM FOR DELIVERING ELECTRONIC BRACHYTHERAPY REPRESENTS THE NEXT GENERATION IN CANCER TREATMENT

Doctor says, "Ability to Deliver Non-Radioactive, Isotope-Free Radiation Therapy Direct to Cancer Sites Has Powerful Implications for Partial Breast Irradiation"

SEATTLE, Wa., and FREMONT, Ca., March 11, 2005 — The delivery of localized radiation treatment directly to cancer sites using high dose rate X-rays on demand has significant potential to improve cancer treatment, according to a recent symposium on Electronic Brachytherapy at the 15th Annual Meeting of the American College of Radiation Oncology (ACRO).

XOFT CEO SCHEDULED TO ADDRESS PIPER JAFFRAY HEALTHCARE CONFERENCE

New CEO to Discuss How Proprietary Platform for Delivering Electronic Brachytherapy Represents the Next Generation in Cancer Treatment

NEW YORK, NY., January 24, 2005 — Xoft, Inc. president and CEO Michael S. Klein has been scheduled to speak at the U.S. Bancorp Piper Jaffray Health Care Conference on January 27, 2005. The company is the developer of Electronic Brachytherapy, a proprietary platform system for delivering non-radioactive, isotope-free radiation therapy directly to cancer sites. Klein, who brings to Xoft extensive breast health and radiation oncology expertise from his prior leadership roles at R2 Technology and Varian, will address how the ability to deliver localized radiation treatment using high dose rate x-rays on demand in virtually any clinical setting, will allow greater patient access and physician adoption.

Media Contact:
Chris K. Joseph
Xoft, Inc.
510-339-2293
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it